admin November 19, 2020

Efficacy of Circulating Tumor Cell Count-Driven vs …
This phase 3 randomized clinical trial assesses the efficacy of a clinician-driven treatment choice vs a circulating tumor cell count-driven choice for first-line treatment among women with hormone receptor-positive, ERBB2-negative metastatic breast cancer.


Tyrosine Kinase Inhibitors Market Size 2020 | Brief …
New Jersey, United States,- Market Research Intellect recently added the Tyrosine Kinase Inhibitors Market research report which provides an in-depth scenario analysis of the market size, share, demand, growth, trends, and forecast for the market from 2020 to 2027. The report covers the impact analysis of the COVID-19 pandemic. The COVID-19 pandemic has affected export-import, demand, and …


Efficacy and Safety of Nivolumab Plus Ipilimumab in …
Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker’s bureaus, stock ownership or options, expert testimony, royalties, donation of medical …


ESMO consensus conference recommendations on the …
A melanoma consensus conference, organised by the ESMO Guidelines Committee, was attended by 32 experts from 14 countries • The experts compiled recommendations (with supporting evidence) on controversial topics in melanoma management


Practical use of insulin degludec/insulin aspart in a …
1 INTRODUCTION. Type 2 diabetes (T2D) is a complex, progressive disease; many people require insulin treatment for glycaemic control. 1 Basal insulin products are used to supplement residual endogenous insulin secretion throughout the day and improve fasting plasma glucose (FPG), while bolus insulins are used to address prandial insulin requirements and limit postprandial hyperglycaemia.


Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven …
NRG1 fusions activate ErbB signaling and have been identified as oncogenic drivers in multiple solid tumor types. Afatinib is a pan‐ErbB family inhibitor authorized for the treatment of advanced non‐small cell lung cancer that may be effective in NRG1 fusion‐driven tumors.; This report summarizes six previously unpublished cases of NRG1 fusion‐driven cancers treated with afatinib …


IMpower110: Interim overall survival (OS) analysis of a …
Late-breaking and deferred publication abstracts NSCLC, metastatic LBA78 IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1—selected NSCLC D. Spigel, 1 F. de Marinis, 2 G. Giaccone, 3 N. Reinmuth, 4 A. Vergnenegre, 5 C.H. Barrios, 6 M. Morise, 7 E. Felip, 8 Z.G …


First‐line pembrolizumab vs chemotherapy in metastatic non …
1 INTRODUCTION. Lung cancer is the leading cause of cancer‐related deaths worldwide 1 and represents approximately 20% of all cancer‐related deaths in Japan. 2 Platinum‐based chemotherapy has historically been the standard first‐line treatment for patients with advanced‐stage non‐small‐cell lung cancer (NSCLC), particularly those without targetable EGFR and ALK alterations 3-5 …


Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised …
AGO‐OVAR 12 investigated the effect of adding the oral triple angiokinase inhibitor nintedanib to standard front‐line chemotherapy for advanced ovarian cancer. At the primary analysis, nintedanib d…


COPD exacerbations: management and hospital discharge …
Introduction. Chronic Obstructive Pulmonary Disease (COPD) is a serious pulmonary condition, which is slowly progressive with systemic repercussions; it mainly affects people over 40 years old. 1 However, COPD is preventable and treatable. Many patients experience COPD exacerbations and some of these require Emergency Room (ER) visits and hospitalizations.